Tags

Type your tag names separated by a space and hit enter

The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis.
J Gen Intern Med. 2005 Dec; 20(12):1151-8.JG

Abstract

BACKGROUND

Exogenous melatonin has been increasingly used in the management of sleep disorders.

PURPOSE

To conduct a systematic review of the efficacy and safety of exogenous melatonin in the management of primary sleep disorders.

DATA SOURCES

A number of electronic databases were searched. We reviewed the bibliographies of included studies and relevant reviews and conducted hand-searching.

STUDY SELECTION

Randomized controlled trials (RCTs) were eligible for the efficacy review, and controlled trials were eligible for the safety review.

DATA EXTRACTION

One reviewer extracted data, while the other verified data extracted. The Random Effects Model was used to analyze data.

DATA SYNTHESIS

Melatonin decreased sleep onset latency (weighted mean difference [WMD]: -11.7 minutes; 95% confidence interval [CI]: -18.2, -5.2)); it was decreased to a greater extent in people with delayed sleep phase syndrome (WMD: -38.8 minutes; 95% CI: -50.3, -27.3; n=2) compared with people with insomnia (WMD: -7.2 minutes; 95% CI: -12.0, -2.4; n=12). The former result appears to be clinically important. There was no evidence of adverse effects of melatonin.

CONCLUSIONS

There is evidence to suggest that melatonin is not effective in treating most primary sleep disorders with short-term use (4 weeks or less); however, additional large-scale RCTs are needed before firm conclusions can be drawn. There is some evidence to suggest that melatonin is effective in treating delayed sleep phase syndrome with short-term use. There is evidence to suggest that melatonin is safe with short-term use (3 months or less).

Links

Publisher Full Text
ncbi.nlm.nih.gov
onlinelibrary.wiley.com
PMC Free PDF
Aggregator Full Text

Authors+Show Affiliations

Buscemi N
Capital Health Evidence-based Practice Centre, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada. nina.buscemi@ualberta.ca
Vandermeer B
No affiliation info available
Hooton N
No affiliation info available
Pandya R
No affiliation info available
Tjosvold L
No affiliation info available
Hartling L
No affiliation info available
Baker G
No affiliation info available
Klassen TP
No affiliation info available
Vohra S
No affiliation info available

MeSH

HumansHypnotics and SedativesMelatoninSleep Wake DisordersTreatment Outcome

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Systematic Review

Language

eng

PubMed ID

16423108

Clinical Trial Links

Understanding Sleep Problems in Children With Autism Spectrum Disorder
Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension

Citation

Buscemi, Nina, et al. "The Efficacy and Safety of Exogenous Melatonin for Primary Sleep Disorders. a Meta-analysis." Journal of General Internal Medicine, vol. 20, no. 12, 2005, pp. 1151-8.
Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005;20(12):1151-8.
Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., Baker, G., Klassen, T. P., & Vohra, S. (2005). The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. Journal of General Internal Medicine, 20(12), 1151-8.
Buscemi N, et al. The Efficacy and Safety of Exogenous Melatonin for Primary Sleep Disorders. a Meta-analysis. J Gen Intern Med. 2005;20(12):1151-8. PubMed PMID: 16423108.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. AU - Buscemi,Nina, AU - Vandermeer,Ben, AU - Hooton,Nicola, AU - Pandya,Rena, AU - Tjosvold,Lisa, AU - Hartling,Lisa, AU - Baker,Glen, AU - Klassen,Terry P, AU - Vohra,Sunita, PY - 2006/1/21/pubmed PY - 2006/7/26/medline PY - 2006/1/21/entrez SP - 1151 EP - 8 JF - Journal of general internal medicine JO - J Gen Intern Med VL - 20 IS - 12 N2 - BACKGROUND: Exogenous melatonin has been increasingly used in the management of sleep disorders. PURPOSE: To conduct a systematic review of the efficacy and safety of exogenous melatonin in the management of primary sleep disorders. DATA SOURCES: A number of electronic databases were searched. We reviewed the bibliographies of included studies and relevant reviews and conducted hand-searching. STUDY SELECTION: Randomized controlled trials (RCTs) were eligible for the efficacy review, and controlled trials were eligible for the safety review. DATA EXTRACTION: One reviewer extracted data, while the other verified data extracted. The Random Effects Model was used to analyze data. DATA SYNTHESIS: Melatonin decreased sleep onset latency (weighted mean difference [WMD]: -11.7 minutes; 95% confidence interval [CI]: -18.2, -5.2)); it was decreased to a greater extent in people with delayed sleep phase syndrome (WMD: -38.8 minutes; 95% CI: -50.3, -27.3; n=2) compared with people with insomnia (WMD: -7.2 minutes; 95% CI: -12.0, -2.4; n=12). The former result appears to be clinically important. There was no evidence of adverse effects of melatonin. CONCLUSIONS: There is evidence to suggest that melatonin is not effective in treating most primary sleep disorders with short-term use (4 weeks or less); however, additional large-scale RCTs are needed before firm conclusions can be drawn. There is some evidence to suggest that melatonin is effective in treating delayed sleep phase syndrome with short-term use. There is evidence to suggest that melatonin is safe with short-term use (3 months or less). SN - 1525-1497 UR - https://www.unboundmedicine.com/medline/citation/16423108/full_citation L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0884-8734&date=2005&volume=20&issue=12&spage=1151 DB - PRIME DP - Unbound Medicine ER -